查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726269

全球糖尿病視網膜病變市場：市場規模、佔有率、趨勢分析（按類型、管理方法和地區）、細分市場預測（2025-2030 年）

Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative Diabetic Retinopathy), By Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

糖尿病視網膜病變市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，全球糖尿病視網膜病變市場預計到 2030 年將達到 137.7 億美元，預測期內的複合年成長率為 6.4%。

各個地區糖尿病盛行率的上升以及人們對糖尿病視網膜病變 (DR) 的有效管理和有效治療重要性的認知不斷提高是主要的市場驅動力。糖尿病視網膜病變若未及時治療，會導致嚴重的視力障礙，甚至失明。醫療保健基礎設施的改善和現代治療方法的增加預計將推動市場成長。

多個地區糖尿病確診人數的大幅增加也促進了該市場的成長。此外，人們越來越意識到早期檢測和有效管理血糖值的重要性，這也推動了市場的成長。此外，與糖尿病相關的失明病例增加有關的令人震驚的統計數據也在不斷增加，預計這將支持該市場的成長。

根據美國糖尿病協會的報告，糖尿病患者有青光眼、白內障和黃斑部水腫等眼科疾病的風險。根據美國疾病管制與預防中心的數據，美國約有 3,840 萬人患有糖尿病。

糖尿病視網膜病變市場：分析概述

  • 到 2024 年，非增生性糖尿病視網膜病變將佔據市場主導地位，佔有率超過 70.0%。
  • 預計在預測期內，雷射手術將以最快的複合年成長率成長。
  • 抗 VEGF 管理領域在 2024 年佔據最大的市場佔有率，為 92.3%。
  • 醫療保健投資的增加和技術進步促進了市場的成長。
  • 由於人們認知的提高、醫療保健基礎設施的完善以及抗 VEGF 藥物的高市場滲透率，北美在全球市場佔據主導地位。
  • 2024 年 9 月，印度國家監管機構核准了Remidio Medios DR AI，這是一款眼科 AI 軟體，可促進可轉診 DR 的自動檢測。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 糖尿病視網膜病變市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 糖尿病視網膜病變市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章糖尿病視網膜病變市場：按類型估計和趨勢分析

  • 按類型分類的儀表板
  • 糖尿病視網膜病變市場：依類型波動分析
  • 全球糖尿病視網膜病變市場：市場規模預測與趨勢分析（按類型）（2018-2030 年）
  • 增生性糖尿病視網膜病變
  • 非增生性糖尿病視網膜病變

第5章糖尿病視網膜病變市場：依管理方法的估計與趨勢分析

  • 管理儀表板
  • 糖尿病視網膜病變市場：依管理方法的差異分析
  • 全球糖尿病視網膜病變市場：市場規模預測與趨勢分析（按管理方法）（2018-2030 年）
  • 抗VEGF
  • 眼內類固醇注射
  • 雷射手術
  • 玻璃體切除手術

第6章糖尿病視網膜病變市場：按地區估計和趨勢分析

  • 市場儀表板：按地區
  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 連續生物加工市場：按地區分類的關鍵要點
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 泰國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要企業熱力圖分析（2024年）
  • 公司簡介
    • Bayer AG
    • AbbVie Inc.
    • Novartis AG
    • Oxurion NV.
    • Sirnaomics, Inc.
    • Alimera Sciences
    • Ampio Pharmaceuticals Inc.
    • BCN Peptides
    • Kowa Company, Ltd.
    • Genentech, Inc.
Product Code: 978-1-68038-466-6

Diabetic Retinopathy Market Growth & Trends:

The global diabetic retinopathy market is anticipated to reach USD 13.77 billion by 2030 and expand at a CAGR of 6.4% during the forecast period, according to a new report by Grand View Research, Inc. Rising incidence of diabetes in multiple regions and growing awareness regarding the significance of efficient management and effective treatment of Diabetic Retinopathy (DR) are key market drivers. If not treated in time, DR may result in severe vision impairment or even blindness. Improved healthcare infrastructure and increasing accessibility to modern treatments are expected to fuel market growth.

The significant increase in the number of individuals diagnosed with diabetes across multiple regions contributes to growth of this market. Rising awareness regarding the importance of early detection and effective management of blood glucose levels, which reduces the chances of DR, also fuels the market growth. Furthermore, the alarming statistics related to the increasing cases of diabetes-related blindness also increase are expected to support growth of this market.

A report from the American Diabetes Association states that people with diabetes are at risk of developing eye diseases, such as glaucoma, cataracts, and macular edema. DR is considered one of the main reasons for blindness in the U.S. According to the U.S. Centers for Disease Control and Prevention, nearly 38.4 million individuals have diabetes in the U.S.

Diabetic Retinopathy Market Report Highlights:

  • Non-proliferative diabetic retinopathy dominated the market with more than 70.0% share in 2024 owing increasing awareness regarding importance of early detection and timely treatment.
  • Laser surgery is expected to grow at the fastest CAGR over the forecast period.
  • The anti-VEGF management segment held the largest market share of 92.3% in 2024.
  • The rise in healthcare investments and advancements in technology contribute to market growth.
  • North America dominated the global market owing to increasing awareness, sophisticated healthcare infrastructure, and high market penetration of anti-VEGF drugs.
  • In September 2024, India's national regulatory authority approved an ophthalmic AI software, Remidio Medios DR AI, which facilitates the automatic detection of referable DRs.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Management
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and Forecasts Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. Management Outlook
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Diabetic Retinopathy Market Analysis tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Diabetic Retinopathy Market: Type Movement Analysis
  • 4.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Proliferative Diabetic Retinopathy
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Non-Proliferative Diabetic Retinopathy
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis

  • 5.1. Management Segment Dashboard
  • 5.2. Diabetic Retinopathy Market: Management Movement Analysis
  • 5.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Management, 2018 to 2030 (USD Million)
  • 5.4. Anti-VEGF
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Intraocular Steroid Injection
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Laser Surgery
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Vitrectomy
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Continuous Bioprocessing Market By Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key Country Dynamics
      • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.1.3. Competitive Scenario
      • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.2.3. Competitive Scenario
      • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Mexico
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key Country Dynamics
      • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.1.3. Competitive Scenario
      • 6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.6.3. Competitive Scenario
      • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.7.3. Competitive Scenario
      • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.8.3. Competitive Scenario
      • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key Country Dynamics
      • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.1.3. Competitive Scenario
      • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.1.3. Competitive Scenario
      • 6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Argentina
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.2.3. Competitive Scenario
      • 6.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.1.3. Competitive Scenario
      • 6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.2.3. Competitive Scenario
      • 6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.3.3. Competitive Scenario
      • 6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.4.3. Competitive Scenario
      • 6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key Company Heat Map Analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Bayer AG
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. AbbVie Inc.
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Novartis AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Oxurion NV.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Sirnaomics, Inc.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Alimera Sciences
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Ampio Pharmaceuticals Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. BCN Peptides
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Kowa Company, Ltd.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Genentech, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 5 U.S. diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 7 Canada diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 8 Canada diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 9 Mexico diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 10 Mexico diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 11 Europe diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 12 Europe diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 14 UK diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 15 UK diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 16 Germany diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 17 Germany diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 18 France diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 19 France diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 20 Italy diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 21 Italy diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 22 Spain diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 23 Spain diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 24 Denmark diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 25 Denmark diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 26 Sweden diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 27 Sweden diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 28 Norway diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 29 Norway diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 33 Japan diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 34 Japan diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 35 China diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 36 China diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 37 India diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 38 India diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 39 South Korea diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 40 South Korea diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 41 Thailand diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 42 Thailand diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 43 Australia diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 44 Australia diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 45 Latin America diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 46 Latin America diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 47 Latin America surgical ablation market, by management, 2018 - 2030 (USD Million)
  • Table 48 Brazil diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 49 Brazil diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 50 Argentina diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 51 Argentina diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 52 MEA diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 53 MEA diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 54 MEA diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 55 South Africa diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 56 South Africa diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 59 UAE diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 60 UAE diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 61 Kuwait diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait diabetic retinopathy market, by management, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Diabetic retinopathy market: market outlook
  • Fig. 10 Diabetic retinopathy competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Diabetic retinopathy market driver impact
  • Fig. 16 Diabetic retinopathy market restraint impact
  • Fig. 17 Diabetic retinopathy market strategic initiatives analysis
  • Fig. 18 Diabetic retinopathy market: Type movement analysis
  • Fig. 19 Diabetic retinopathy market: Type outlook and key takeaways
  • Fig. 20 Proliferative diabetic retinopathy market estimates and forecast, 2018 - 2030
  • Fig. 21 Non-proliferative diabetic retinopathy estimates and forecast, 2018 - 2030
  • Fig. 22 Diabetic retinopathy market: Management movement analysis
  • Fig. 23 Diabetic retinopathy market: Management outlook and key takeaways
  • Fig. 24 Anti-VEGF market estimates and forecasts, 2018 - 2030
  • Fig. 25 Intraocular steroid injection market estimates and forecasts,2018 - 2030
  • Fig. 26 Laser surgery market estimates and forecasts, 2018 - 2030
  • Fig. 27 Vitrectomy market estimates and forecasts, 2018 - 2030
  • Fig. 28 Global diabetic retinopathy market: regional movement analysis
  • Fig. 29 Global diabetic retinopathy market: regional outlook and key takeaways
  • Fig. 30 North America market estimates and forecasts, 2018 - 2030
  • Fig. 31 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 33 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 37 France market estimates and forecasts, 2018 - 2030
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 40 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 41 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 42 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 45 China market estimates and forecasts, 2018 - 2030
  • Fig. 46 India market estimates and forecasts, 2018 - 2030
  • Fig. 47 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 49 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 52 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 53 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 54 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 56 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 57 Kuwait market estimates and forecasts, 2018 - 2030